

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
IN RE PCT NATIONAL STAGE APPLICATION OF                      ART UNIT: 1627  
BHATNAGAR, AJAY S. ET AL.    EXAMINER: JAVANMARD, SAHAR  
INTERNATIONAL APPLICATION NO: PCT/EP03/08377  
FILED: JULY 29, 2003  
U.S. APPLICATION NO: 10/521928  
35 USC §371 DATE: JANUARY 21, 2005  
FOR: COMBINATION OF AN AROMATASE INHIBITOR WITH A  
      BISPHOSPHONATE

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed January 11, 2006.
- ☒ Filed concurrently with a Request for Continued Examination, therefore no fees are required

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936(862) 778-1202  
Date: *October 20, 2010*

Respectfully submitted,

*Jennifer C. Chapman*  
\_\_\_\_\_  
Jennifer C. Chapman  
Attorney for Applicant  
Reg. No. 47,487